Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

NCT07745504

Not Yet RecruitingPhase 3

Sponsor: Novo Nordisk A/S

Conditions: Overweight, Obesity

Interventions: Cagrilintide, Placebo cagrilintide, Placebo semaglutide

Countries: United States, Greece, Hungary, Portugal, Serbia, Sweden

The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight. Participants will either get cagrilintide, the active study medicine being tested or placebo, a medicine that has no active medicine in it. Which treatment participants get is decided by chance. Cagrilintide is a new medicine under development that doctors cannot prescribe yet, but it has been tested in humans before. Participants will be in this clinical study for about 9 months.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion criteria:

* Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
* Male or female (sex assigned at birth, inclusive of all gender identities).
* Age 18 years or above at the time of signing the informed consent.
* Body mass index (BMI) greater than or equal to (\>=) 30.0 kilograms per square meter (kg/m\^2), or BMI \>= 27.0 kg/m\^2 with the presence of at least one weight related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.

Exclusion criteria:

* History of Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D).
* Previous dosing of marketed or non-marketed amylin-based compounds.
* Treatment, or intention to initiate treatment, with any medication prescribed for the indication of weight management within 180 days before screening.
Locations (36)
  • Conyers, Georgia, United States
  • Honolulu, Hawaii, United States
  • Oak Park, Illinois, United States
  • Indianapolis, Indiana, United States
  • Lexington, Kentucky, United States
  • Greensboro, North Carolina, United States
  • Wilmington, North Carolina, United States
  • North Charleston, South Carolina, United States
  • Newport News, Virginia, United States
  • Richmond, Virginia, United States
  • Winchester, Virginia, United States
  • Athens, Greece
  • Athens, Greece
  • Irakleio, Greece
  • Peristeri, Greece
  • Thessaloniki, Greece
  • Thessaloniki, Greece
  • Kalocsa, Bács-Kiskun county, Hungary
  • Nyíregyháza, Szabolcs-Szatmar Varmegye, Hungary
  • Kecskemét, Hungary
  • Szeged, Hungary
  • Caldas da Rainha, Portugal
  • Figueira da Foz Municipality, Portugal
  • Leiria, Portugal
  • Lisbon, Portugal
  • Lisbon, Portugal
  • Vila Nova de Gaia, Portugal
  • Belgrade, Serbia
  • Kamenitz, Serbia
  • Niš, Serbia
  • + 6 more on CT.gov